The global immunotherapeutic drugs market is expected to grow at a significant CAGR during the forecast period (2021-2027). Immunotherapies as an additional therapy in severe COVID-19 instances, according to research investigations. Immunotherapies based on inflammatory cytokine neutralisation, immunomodulation, and passive viral neutralisation can reduce inflammation, inflammation-associated lung damage, and viral load while also avoiding ICU admission and mechanical ventilation. As several companies are actively engaged in creating immunotherapy-based medications or vaccines for COVID-19, the impact of COVID-19 on the immunotherapeutic drugs market is positive. BioNTech SE is now undertaking phase III clinical research in healthy volunteers to examine the safety, tolerability, and immunogenicity of BNT162b2 against COVID-19 in partnership with Pfizer Inc.
A full report of Immunotherapeutic Drugs Market is available at: https://www.omrglobal.com/industry-reports/immunotherapeutic-drugs-market
The increased adoption of targeted therapy over traditional therapy, the emergence of biosimilars, the rising prevalence of chronic diseases and lifestyle disorders, and the rising need for monoclonal antibodies are all contributing to the growth of the immunotherapeutic drugs market. Furthermore, factors such as rising research collaborations, the number of research laboratories, and pharmaceutical and biotechnology companies’ direct and indirect R&D spending will all contribute to the market growth in the future years. For instance, Gilead Sciences Inc. and Humanigen Inc. teamed together in 2019 to explore lenzilumab in combination with YESCARTA in patients with relapsed or refractory diffuse large B-cell lymphoma. Globally, the frequency of various chronic diseases has been steadily increasing, necessitating immune-based therapy in many cases. Cancer, kidney failure, autoimmune and inflammatory illnesses, and cardiac problems are among the most common chronic diseases. According to Versus Arthritis, nearly 18% of adults over 45 years old in England had osteoarthritis of the knee in 2019.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/immunotherapeutic-drugs-market
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered
- Regions Covered- Globally
- Competitive Landscape: F. Hoffman L-Roche AG, Novartis International AG, AbbVie Inc., and Amgen Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Immunotherapeutic Drugs Market Report Segmentation
By Drug
• Monoclonal Antibodies
• Vaccines
• Interferons Alpha and Beta
• Interleukins
• Other Types of Drugs
By Therapy Area
• Cancer
• Autoimmune and Inflammatory Diseases
• Infectious Diseases
• Other Therapy Areas
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
